Merger to create a Nasdaq-listed company focusing on targeted protein degradation technology with
three degrader programs in or about to initiate Phase 1 clinical trials – two for the treatment of cancer and
one for the treatment of acute and chronic pain
Combined company expected to have approximately $65 million of cash and cash equivalents at close to
provide funding through multiple clinical milestones and expected runway through 2026
As part of merger agreement, Pulmatrix intends to divest its assets including its acute migraine candidate,
PUR3100, and other development candidates based on its iSPERSE™ technology
Cullgen and Pulmatrix will host an informational webcast about the proposed merger that will be made
available to access at 12:00 pm ET today
Webcast Information
Management will host an informational webcast that will be made available to access at 12:00 pm ET today. A link to the webcast can be found in the Investor Events and Presentations section of the Pulmatrix website at www.pulmatrix.com and in the News & Events section of Cullgen's website at www.cullgen.com.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.